Infectious Disease Ontology

Technological developments have resulted in tremendous increases in the volume and diversity of the data and information that must be processed in the course of biomedical and clinical research and practice. Researchers are at the same time under ever greater pressure to share data and to take steps to ensure that data resources are interoperable. The use of ontologies to annotate data has proven successful in supporting these goals and in providing new possibilities for the automated processing of data and information. In this chapter, we describe different types of vocabulary resources and emphasize those features of formal ontologies that make them most useful for computational applications. We describe current uses of ontologies and discuss future goals for ontology-based computing, focusing on its use in the field of infectious diseases. We review the largest and most widely used vocabulary resources relevant to the study of infectious diseases and conclude with a description of the Infectious Disease Ontology (IDO) suite of interoperable ontology modules that together cover the entire infectious disease domain

Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy

<p>Abstract</p> <p>Background</p> <p>Decision analysis in hospital-based settings is becoming more common place. The application of modeling and simulation approaches has likewise become more prevalent in order to support decision analytics. With respect to clinical decision making at the level of the patient, modeling and simulation approaches have been used to study and forecast treatment options, examine and rate caregiver performance and assign resources (staffing, beds, patient throughput). There us a great need to facilitate pharmacotherapeutic decision making in pediatrics given the often limited data available to guide dosing and manage patient response. We have employed nonlinear mixed effect models and Bayesian forecasting algorithms coupled with data summary and visualization tools to create drug-specific decision support systems that utilize individualized patient data from our electronic medical records systems.</p> <p>Methods</p> <p>Pharmacokinetic and pharmacodynamic nonlinear mixed-effect models of specific drugs are generated based on historical data in relevant pediatric populations or from adults when no pediatric data is available. These models are re-executed with individual patient data allowing for patient-specific guidance via a Bayesian forecasting approach. The models are called and executed in an interactive manner through our web-based dashboard environment which interfaces to the hospital's electronic medical records system.</p> <p>Results</p> <p>The methotrexate dashboard utilizes a two-compartment, population-based, PK mixed-effect model to project patient response to specific dosing events. Projected plasma concentrations are viewable against protocol-specific nomograms to provide dosing guidance for potential rescue therapy with leucovorin. These data are also viewable against common biomarkers used to assess patient safety (e.g., vital signs and plasma creatinine levels). As additional data become available via therapeutic drug monitoring, the model is re-executed and projections are revised.</p> <p>Conclusion</p> <p>The management of pediatric pharmacotherapy can be greatly enhanced via the immediate feedback provided by decision analytics which incorporate the current, best-available knowledge pertaining to dose-exposure and exposure-response relationships, especially for narrow therapeutic agents that are difficult to manage.</p

Evidence for B- -> tau- nu_bar with a Semileptonic Tagging Method

We present a measurement of the decay B- -> tau- nu_bar using a data sample containing 657 million BB_bar pairs collected at the Upsilon(4S) resonance with the Belle detector at the KEKB asymmetric-energy e+e- collider. A sample of BB_bar pairs are tagged by reconstructing one B meson decaying semileptonically. We detect the B- -> tau- nu_bar candidate in the recoil. We obtain a signal with a significance of 3.6 standard deviations including systematic uncertainties, and measure the branching fraction to be Br(B- -> tau- nu_bar) = [1.54+0.38-0.37(stat)+0.29-0.31(syst)]*10^-4. This result confirms the evidence for B- -> tau- nu_bar obtained in a previous Belle measurement that used a hadronic B tagging method.Comment: 7 pages, 3 figures, corrected references, to appear in PRD-R

Study of the decays B->D_s1(2536)+ anti-D(*)

We report a study of the decays B -> D_s1(2536)+ anti-D(*), where anti-D(*) is anti-D0, D- or D*-, using a sample of 657 x 10^6 B anti-B pairs collected at the Upsilon(4S) resonance with the Belle detector at the KEKB asymmetric-energy e+e- collider. The branching fractions of the decays B+ -> D_s1(2536)+ anti-D0, B0 -> D_s1(2536)+ D- and B0 -> D_s1(2536)+ D*- multiplied by that of D_s1(2536)+ -> (D*0K+ + D*+K0) are found to be (3.97+-0.85+-0.56) x 10^-4, (2.75+-0.62+-0.36) x 10^-4 and (5.01+-1.21+-0.70) x 10^-4, respectively.Comment: 6 pages, 2 figues, submitted to PRD (RC

Measurements of B decays to two kaons

We report measurements of B meson decays to two kaons using 253 fb(-1) of data collected with the Belle detector at the KEKB energy-asymmetric e(+)e(-) collider. We find evidence for signals in B+->(K) over bar K-0(+) and B-0-> K-0(K) over bar (0) with significances of 3.0 sigma and 3.5 sigma, respectively. (Charge-conjugate modes are included.) The corresponding branching fractions are measured to be B(B+->(K) over bar K-0(+))=(1.0 +/- 0.4 +/- 0.1)x10(-6) and B(B-0-> K-0(K) over bar (0))=(0.8 +/- 0.3 +/- 0.1)x10(-6). These decay modes are examples of hadronic b -> d transitions. No signal is observed in the decay B-0-> K+K-, and we set an upper limit of 3.7x10(-7) at 90% confidence level

Measurements of the branching fraction and polarization in B+->rho K-+(*0) decays

We present the results of a study of the charmless vector-vector decay B+->rho K-+(*0), based on 253 fb(-1) of data collected with the Belle detector at the KEKB asymmetric-energy e(+)e(-) collider. We obtain the branching fraction B(B+->rho K-+(*0))=[8.9 +/- 1.7(stat)+/- 1.2(syst)]x10(-6). We also perform a helicity analysis of the rho and K-* vector mesons, and obtain the longitudinal polarization fraction f(L)(B+->rho K-+(*0))=0.43 +/- 0.11(stat)(-0.02)(+0.05)(syst)

Effect of a web-based chronic disease management system on asthma control and health-related quality of life: study protocol for a randomized controlled trial

<p>Abstract</p> <p>Background</p> <p>Asthma is a prevalent and costly disease resulting in reduced quality of life for a large proportion of individuals. Effective patient self-management is critical for improving health outcomes. However, key aspects of self-management such as self-monitoring of behaviours and symptoms, coupled with regular feedback from the health care team, are rarely addressed or integrated into ongoing care. Health information technology (HIT) provides unique opportunities to facilitate this by providing a means for two way communication and exchange of information between the patient and care team, and access to their health information, presented in personalized ways that can alert them when there is a need for action. The objective of this study is to evaluate the acceptability and efficacy of using a web-based self-management system, My Asthma Portal (MAP), linked to a case-management system on asthma control, and asthma health-related quality of life.</p> <p>Methods</p> <p>The trial is a parallel multi-centered 2-arm pilot randomized controlled trial. Participants are randomly assigned to one of two conditions: a) MAP and usual care; or b) usual care alone. Individuals will be included if they are between 18 and 70, have a confirmed asthma diagnosis, and their asthma is classified as not well controlled by their physician. Asthma control will be evaluated by calculating the amount of fast acting beta agonists recorded as dispensed in the provincial drug database, and asthma quality of life using the Mini Asthma Related Quality of Life Questionnaire. Power calculations indicated a needed total sample size of 80 subjects. Data are collected at baseline, 3, 6, and 9 months post randomization. Recruitment started in March 2010 and the inclusion of patients in the trial in June 2010.</p> <p>Discussion</p> <p>Self-management support from the care team is critical for improving chronic disease outcomes. Given the high volume of patients and time constraints during clinical visits, primary care physicians have limited time to teach and reinforce use of proven self-management strategies. HIT has the potential to provide clinicians and a large number of patients with tools to support health behaviour change.</p> <p>Trial Registration</p> <p>Current Controlled Trials <a href="http://www.controlled-trials.com/ISRCTN34326236">ISRCTN34326236</a>.</p

Measurement of forward-backward asymmetry and wilson coefficients in B -> K(*)l(+)l(-)

We report the first measurement of the forward-backward asymmetry and the ratios of Wilson coefficients A(9)/A(7) and A(10)/A(7) in B -> K(*)l(+)l(-), where l represents an electron or a muon. We find evidence for the forward-backward asymmetry with a significance of 3.4 sigma. The results are obtained from a data sample containing 386x10(6) (B) over bar pairs that were collected on the Upsilon(4S) resonance with the Belle detector at the KEKB asymmetric-energy e(+)e(-) collider

Measurements of Branching Fractions for B0 --> Ds+pi- and B0-bar --> Ds+K-

We present improved measurements of the branching fractions for the decays B0 --> Ds+pi- and B0-bar --> Ds+K- using a data sample of 657x10^6 BB-bar events collected at the Y(4S) resonance with the Belle detector at the KEKB asymmetric-energy e+e- collider. The results are BF(B0 --> Ds+pi-) = (1.99 +/- 0.26 +/- 0.18)x10^-5 and BF(B0-bar --> Ds+K-) = (1.91 +/- 0.24 +/- 0.17)x10^-5, where the uncertainties are statistical and systematic, respectively. Based on these results, we determine the ratio between amplitudes of the doubly Cabibbo suppressed decay B0 --> D+pi- and the Cabibbo favored decay B0 --> D-pi+, R_Dpi = [1.71 +/- 0.11(stat) +/- 0.09(syst) +/- 0.02(theo)]%, where the last term denotes the theory error.Comment: 7 pages, 10 figures, 2 tables, published in PRD(RC

Measurement of polarization and triple-product correlations in B -> phi K-* decays

We present measurements of decay amplitudes and triple-product correlations in B ->phi K-* decays based on 253 fb(-1) of data recorded at the Upsilon(4S) resonance with the Belle detector at the KEKB e(+)e(-) storage ring. The decay amplitudes for the three different helicity states are determined from the angular distributions of final-state particles. The longitudinal polarization amplitudes are found to be 0.45 +/- 0.05 +/- 0.02 for B-0->phi K-*0 and 0.52 +/- 0.08 +/- 0.03 for B+->phi K*+ decays. CP- and T-odd CP-violating triple-product asymmetries are measured to be consistent with zero